[Asia Economy Reporter Kim Daehyun] Alteogen announced on the 15th that its subsidiary Altos Biologics has decided to raise 29.5 billion KRW through a third-party allotment paid-in capital increase to secure operating funds.
The shares to be issued through this paid-in capital increase are 184,375 preferred shares, with a par value of 500 KRW per share.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
